REMUS Stock Overview
Engages in the marketing, trading, and distribution of pharmaceutical finished formulations and products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Remus Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,446.55 |
| 52 Week High | ₹2,834.75 |
| 52 Week Low | ₹1,200.00 |
| Beta | 0 |
| 1 Month Change | 3.82% |
| 3 Month Change | -1.74% |
| 1 Year Change | 38.61% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 444.65% |
Recent News & Updates
We Ran A Stock Scan For Earnings Growth And Remus Pharmaceuticals (NSE:REMUS) Passed With Ease
Sep 25
Recent updates
We Ran A Stock Scan For Earnings Growth And Remus Pharmaceuticals (NSE:REMUS) Passed With Ease
Sep 25Remus Pharmaceuticals Limited's (NSE:REMUS) P/E Is Still On The Mark Following 28% Share Price Bounce
Aug 20Returns On Capital Signal Tricky Times Ahead For Remus Pharmaceuticals (NSE:REMUS)
Jun 27Concerns Surrounding Remus Pharmaceuticals' (NSE:REMUS) Performance
May 23Remus Pharmaceuticals Limited (NSE:REMUS) Looks Just Right With A 29% Price Jump
May 21Shareholder Returns
| REMUS | IN Healthcare | IN Market | |
|---|---|---|---|
| 7D | -1.5% | -0.2% | -2.1% |
| 1Y | 38.6% | 44.5% | 22.5% |
Return vs Industry: REMUS underperformed the Indian Healthcare industry which returned 44.5% over the past year.
Return vs Market: REMUS exceeded the Indian Market which returned 22.5% over the past year.
Price Volatility
| REMUS volatility | |
|---|---|
| REMUS Average Weekly Movement | 5.6% |
| Healthcare Industry Average Movement | 5.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: REMUS has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: REMUS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 48 | Arpit Shah | remuspharma.com |
Remus Pharmaceuticals Limited engages in the marketing, trading, and distribution of pharmaceutical finished formulations and products in India and internationally. It is involved in trading of active pharmaceutical ingredient, as well as provides technical consultancy services to various distributors and contract manufacturing services. The company offers capsule, cream, eye drop, gel, infusion, inhalation, inhaler, injection, nail lacquer, nasal solution, nasal spray, nebulizer, ointment, ophthalmic, oral gel, oral solution, oral suspension, sachet, suspension, and tablets.
Remus Pharmaceuticals Limited Fundamentals Summary
| REMUS fundamental statistics | |
|---|---|
| Market cap | ₹14.42b |
| Earnings (TTM) | ₹299.01m |
| Revenue (TTM) | ₹4.57b |
48.2x
P/E Ratio3.2x
P/S RatioIs REMUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REMUS income statement (TTM) | |
|---|---|
| Revenue | ₹4.57b |
| Cost of Revenue | ₹3.83b |
| Gross Profit | ₹738.12m |
| Other Expenses | ₹439.11m |
| Earnings | ₹299.01m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 50.75 |
| Gross Margin | 16.17% |
| Net Profit Margin | 6.55% |
| Debt/Equity Ratio | 17.0% |
How did REMUS perform over the long term?
See historical performance and comparisonDividends
0.08%
Current Dividend Yield4%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 03:04 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Remus Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|